Free Cash Flow to Equity (FCFE)
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
Item | Description | The company |
---|---|---|
FCFE | Free cash flow to equity is the cash flow available to Becton, Dickinson & Co. equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made. | Becton, Dickinson & Co. FCFE increased from 2019 to 2020 and from 2020 to 2021. |
Price to FCFE Ratio, Current
No. shares of common stock outstanding | 285,064,629 |
Selected Financial Data (US$) | |
Free cash flow to equity (FCFE) (in millions) | 3,173) |
FCFE per share | 11.13 |
Current share price (P) | 259.64 |
Valuation Ratio | |
P/FCFE | 23.33 |
Benchmarks | |
P/FCFE, Competitors1 | |
Abbott Laboratories | 78.40 |
Cigna Group | 8.80 |
CVS Health Corp. | 4.23 |
Elevance Health Inc. | 13.46 |
Humana Inc. | 9.50 |
Intuitive Surgical Inc. | 244.97 |
Medtronic PLC | 18.42 |
UnitedHealth Group Inc. | 18.33 |
P/FCFE, Sector | |
Health Care Equipment & Services | 20.92 |
P/FCFE, Industry | |
Health Care | 19.55 |
Based on: 10-K (reporting date: 2021-09-30).
1 Click competitor name to see calculations.
If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.
Price to FCFE Ratio, Historical
Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | ||
---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | 284,023,582 | 290,031,363 | 270,459,892 | 268,257,940 | 227,978,328 | 212,319,588 | |
Selected Financial Data (US$) | |||||||
Free cash flow to equity (FCFE) (in millions)2 | 3,173) | 969) | 338) | 3,060) | 9,105) | 614) | |
FCFE per share3 | 11.17 | 3.34 | 1.25 | 11.41 | 39.94 | 2.89 | |
Share price1, 4 | 244.46 | 227.47 | 260.40 | 242.04 | 224.23 | 168.48 | |
Valuation Ratio | |||||||
P/FCFE5 | 21.88 | 68.08 | 208.37 | 21.22 | 5.61 | 58.26 | |
Benchmarks | |||||||
P/FCFE, Competitors6 | |||||||
Abbott Laboratories | 24.52 | 38.42 | 53.19 | — | — | — | |
Cigna Group | 10.98 | 16.30 | 20.76 | — | — | — | |
CVS Health Corp. | 21.23 | 11.93 | 18.52 | — | — | — | |
Elevance Health Inc. | 11.07 | 7.75 | 13.72 | — | — | — | |
Humana Inc. | 11.49 | 8.47 | 11.73 | — | — | — | |
Intuitive Surgical Inc. | 58.39 | 81.15 | 57.31 | — | — | — | |
Medtronic PLC | 38.91 | 23.06 | 26.62 | — | — | — | |
UnitedHealth Group Inc. | 20.11 | 13.93 | 13.90 | — | — | — | |
P/FCFE, Sector | |||||||
Health Care Equipment & Services | 20.14 | 16.68 | 19.46 | — | — | — | |
P/FCFE, Industry | |||||||
Health Care | 16.76 | 17.08 | 13.39 | — | — | — |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
1 Data adjusted for splits and stock dividends.
3 2021 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= 3,173,000,000 ÷ 284,023,582 = 11.17
4 Closing price as at the filing date of Becton, Dickinson & Co. Annual Report.
5 2021 Calculation
P/FCFE = Share price ÷ FCFE per share
= 244.46 ÷ 11.17 = 21.88
6 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/FCFE | Price to free cash flow to equity is cash valuation indicator of stockholders’ equity. | Becton, Dickinson & Co. P/FCFE ratio decreased from 2019 to 2020 and from 2020 to 2021. |